[1]李 博,李春晓.新辅助化疗在宫颈癌治疗中的应用[J].医学信息,2019,32(15):106-108.[doi:10.3969/j.issn.1006-1959.2019.15.034]
　LI Bo,LI Chun-xiao.Application of Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer[J].Journal of Medical Information,2019,32(15):106-108.[doi:10.3969/j.issn.1006-1959.2019.15.034]
点击复制

新辅助化疗在宫颈癌治疗中的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年15期
页码:
106-108
栏目:
临床研究
出版日期:
2019-08-01

文章信息/Info

Title:
Application of Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer
文章编号:
1006-1959（2019）15-0106-03
作者:
李 博1; 李春晓2
佳木斯市中心医院肿瘤内科1，普外科2，黑龙江 佳木斯 154002
Author(s):
LI Bo1; LI Chun-xiao2
Department of Oncology1,Department of General Surgery2,Jiamusi Central Hospital,Jiamusi 154002, Heilongjiang,China
关键词:
新辅助化疗; 手术治疗; 宫颈癌; 术后并发症
Keywords:
Key words：Neoadjuvant chemotherapy; Surgical treatment; Cervical cancer; Postoperative complications
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2019.15.034
文献标志码:
A
摘要:
目的 评价新辅助化疗在宫颈癌治疗中的效果，为宫颈癌治疗工作的开展提供参考。方法 选择我院2016年8月~2018年3月收治的宫颈癌患者60例。以随机数字表法分为对照组和观察组，各30例。对照组接受常规手术治疗，观察组在术前给予新辅助化疗治疗。对比两组宫颈癌患者术中出血量、手术时间、治疗效果以及术后并发症情况、患者治疗效果满意度评分。结果观察组宫颈癌患者手术时间为（144.50±23.50）min，短于对照组的（224.50±28.50）min（P＜0.05）；术后并发症总发生率为16.67%，低于对照组的6.66%（P＜0.05）；观察组治疗效果满意度评分（90.02±2.15）分，高于对照组的（75.50±2.80）分（P＜0.05）；治疗总有效率86.67%，优于对照组的73.33%（P＜0.05）。结论 宫颈癌治疗中于术前进行新辅助化疗，可以提高患者治疗效果、安全性、缩短手术时间，整体预后效果显著。
Abstract:
Abstract：Objective To evaluate the effect of neoadjuvant chemotherapy in the treatment of cervical cancer and provide reference for the development of cervical cancer treatment.Methods 60 patients with cervical cancer admitted to our hospital from August 2016 to March 2018 were selected. They were divided into control group and observation group by random number table method, 30 cases each. The control group received routine surgery and the observation group received neoadjuvant chemotherapy before surgery. The intraoperative blood loss, operation time, treatment effect, postoperative complications, and patient satisfaction satisfaction scores of the two groups of cervical cancer patients were compared.Results The operation time of cervical cancer patients was (144.50±23.50) min, which was shorter than that of the control group (224.50±28.50) min (P<0.05). The total incidence of postoperative complications was 16.67%, which was lower than that of the control group 6.66% (P<0.05). The satisfaction score of the treatment group (90.02±2.15) was higher than that of the control group (75.50±2.80)(P<0.05); the total effective rate of treatment was 86.67%, which was better than 73.33% of the control group (P<0.05).Conclusion Neoadjuvant chemotherapy in the treatment of cervical cancer can improve the treatment effect, safety and shorten the operation time. The overall prognosis is significant.

参考文献/References:

[1]任韧.新辅助化疗在宫颈癌治疗中的应用及临床价值分析[J].中国肿瘤临床与康复,2015,20(12):1399. [2]李翔,鲁艳明,张瑶,等.紫杉醇联合顺铂新辅助化疗在早中期宫颈癌治疗中的临床应用[J].实用药物与临床,2016,19(2):148-151. [3]吴绘春,杨菁.新辅助化疗在宫颈癌治疗中的应用研究[J].中国妇幼健康研究,2016,27(10):1258-1260. [4]廖万清,汤新跃.术前新辅助化疗在局部晚期宫颈癌治疗中的临床价值[J].实用癌症杂志,2015(2):266-268. [5]陈琪,张虹.新辅助化疗在宫颈癌治疗中的作用[J].国际妇产科学杂志,2014(6):606-609. [6]王雅楠.新辅助化疗在治疗ⅠB2-ⅡB期宫颈癌中的应用及其疗效[D].大连医科大学,2015. [7]王国华,李海燕.新辅助化疗在宫颈癌治疗中的应用及价值评述[J].中国农村卫生,2016(12):77.

相似文献/References:

[1]阿布都艾尼窑米吉提.脊柱结核的手术治疗研究进展[J].医学信息,2018,31(01):64.[doi:10.3969/j.issn.1006-1959.2018.01.023]
　Abdugeni·Mijit.Research Progress on Surgical Treatment of Spinal Tuberculosis[J].Journal of Medical Information,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.01.023]
[2]屈欣然.DCE-MRI对局部进展期乳腺癌新辅助化疗的临床指导价值研究[J].医学信息,2018,31(04):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
　QU Xin-ran.Clinical Value of DCE-MRI in Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer[J].Journal of Medical Information,2018,31(15):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
[3]文虹杰,杨华刚,韩 涛,等.胫骨横向骨搬移术治疗糖尿病足的临床效果观察[J].医学信息,2018,31(07):184.[doi:10.3969/j.issn.1006-1959.2018.07.066]
　WEN Hong-jie,YANG Hua-gang,HAN Tao,et al.Clinical Observation on the Treatment of Diabetic Foot with Transverse Tibial Bone Movement[J].Journal of Medical Information,2018,31(15):184.[doi:10.3969/j.issn.1006-1959.2018.07.066]
[4]韩林东,李 明.青少年特发性脊柱侧弯非手术治疗研究进展[J].医学信息,2018,31(08):28.[doi:10.3969/j.issn.1006-1959.2018.08.010]
　HAN Lin-dong,LI Ming.Progress in Non-operative Treatment of Adolescent Idiopathic Scoliosis[J].Journal of Medical Information,2018,31(15):28.[doi:10.3969/j.issn.1006-1959.2018.08.010]
[5]王文重,伊 扬,董晓昕,等.食管癌患者新辅助化疗前后生理指标变化及意义[J].医学信息,2022,35(09):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
　WANG Wen-zhong,YI Yang,DONG Xiao-xin,et al.Changes and Significance of Physiological Indexes in Esophageal Cancer Patients Before and After Neoadjuvant Chemotherapy[J].Journal of Medical Information,2022,35(15):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
[6]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
　ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Journal of Medical Information,2022,35(15):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[7]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(15):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[8]苏 志,吴 蔚,吴智钢,等.含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察[J].医学信息,2018,31(21):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
　SU Zhi,WU Wei,WU Zhi-gang,et al.Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for OsteosarcomaC[J].Journal of Medical Information,2018,31(15):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
[9]高 翔,夏 亮,杨亚斌.原发性闭角型青光眼的治疗[J].医学信息,2018,31(23):51.[doi:10.3969/j.issn.1006-1959.2018.23.015]
　GAO Xiang,XIA Liang,YANG Ya-bin.Treatment of Primary Angleclosure Glaucoma[J].Journal of Medical Information,2018,31(15):51.[doi:10.3969/j.issn.1006-1959.2018.23.015]
[10]王绥能,梁贤文,孙 光,等.伊立替康新辅助化疗在进展期胃癌的临床意义[J].医学信息,2018,31(24):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]
　WANG Sui-neng,LIANG Xian-wen,SUN Guang,et al.Clinical Significance of Irinotecan Neoadjuvant Chemotherapy in Advanced Gastric Carcinoma[J].Journal of Medical Information,2018,31(15):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]

更新日期/Last Update: 2019-08-01